Large Scale Biology Corporation Announces Breakthrough Diagnostic Technology
Thursday December 18, 7:01 am ET
VACAVILLE, Calif.--(BUSINESS WIRE)--Dec. 18, 2003--Large Scale Biology Corporation (Nasdaq:LSBC - News) announced today its plans to commercialize through a wholly-owned subsidiary, Eclipse Diagnostics, Inc. (http://www.eclipsediagnostics.com/), a revolutionary new diagnostic product called BAMF(TM) Technology that enables breakthrough detection of cancer and other diseases through non-invasive, serum-based (blood) tests. BAMF(TM) Technology is a proprietary pattern recognition discovery platform that detects key proteins found in blood, known as biomarkers, which act as biological "fingerprints" to classify life-threatening diseases such as cancer.
In our ongoing research collaborations with Lance Liotta, M.D., Ph.D. and Emanuel Petricoin, Ph.D., respectively the co-directors of the National Cancer Institute and Food and Drug Administration (NCI/FDA) Clinical Proteomics Program, BAMF(TM) Technology successfully diagnosed 100% of the ovarian cancer patients vs. normal using statistically relevant mass spectrometry data sets publicly available from the NCI/FDA study (http://clinicalproteomics.steem.com/).
Early diagnosis of ovarian cancer has been shown to yield cures at a rate of 95%, whereas late stage discovery results in a cure rate of only 35%. BAMF(TM) Technology provides an accurate yet cost-effective method of diagnosing ovarian cancer as well as other diseases. Ongoing collaborative research studies with the NCI/FDA include lung, breast, and pancreatic cancers as well as additional ovarian cancer data.
Kevin J. Ryan, President and CEO of LSBC, stated that "the BAMF(TM) Technology builds on the long history of our Company in the proteomics field and will fulfill the promise of proteomics for cost-effective medical diagnosis, drug and biomarker discovery and clinical trial management. All proteomics analysis for the Company will be headquartered in Vacaville as these operations are transitioned to Eclipse Diagnostics, Inc." |
